clinical outcomes – mycolab.ai

Naturalistic psychedelic therapy: The role of relaxation and subjective drug effects in antidepressant response

mycolabadmin

Researchers studied how LSD and psilocybin work in real-world therapy settings in Switzerland. They found that these compounds effectively reduced depression symptoms in patients who hadn’t responded to other treatments. Surprisingly, the feeling of relaxation during the session was more important for improvement than having intense mystical experiences. The therapy was generally safe, with side effects that resolved quickly.

Comparing Antidepressant Effects of Psilocybin-Assisted Psychotherapy in Individuals That Were Unmedicated at Initial Screening Versus Individuals Discontinuing Medications for Study Participation

mycolabadmin

This study compared how well psilocybin therapy works for people with treatment-resistant depression depending on whether they were already off antidepressants or had stopped taking them for the study. The researchers found that both groups improved similarly in depression and anxiety symptoms after receiving psilocybin with therapy support. These results suggest that stopping antidepressants before psilocybin treatment may not reduce its effectiveness, though more research is needed to fully understand the relationship between medication status and treatment outcomes.

Psychedelics and Neuroplasticity: A Systematic Review Unraveling the Biological Underpinnings of Psychedelics

mycolabadmin

This review examines how psychedelic substances like psilocybin and LSD affect brain structure and function. Research shows these compounds can increase BDNF (a protein crucial for brain health) and promote the growth of new neurons and connections between brain cells. These biological changes may explain why psychedelics have shown promise in treating depression and anxiety, with effects lasting weeks after a single dose.

Biological markers of treatment response to serotonergic psychedelic therapies: a systematic review

mycolabadmin

This review examines how scientists can predict which patients will benefit most from psychedelic-assisted therapy for depression by measuring biological markers in the brain and blood. Researchers found that certain brain changes and protein levels—particularly involving the amygdala, specific brain regions, and inflammation markers—appear linked to treatment success. While the current studies are small, they suggest that measuring these biological markers could eventually help doctors personalize psychedelic treatments for depression.

Psilocybin-assisted group psychotherapy and mindfulness-based stress reduction for frontline healthcare provider COVID-19-related depression and burnout: A randomized controlled trial

mycolabadmin

Researchers tested whether combining psilocybin therapy with mindfulness training could better treat depression and burnout in frontline healthcare workers than mindfulness training alone. Twenty-five doctors and nurses participated in the study, with some receiving mindfulness training combined with psilocybin therapy in a group setting, while others received mindfulness training only. After two weeks, those who received the combined treatment showed significantly greater improvements in depression symptoms and burnout, with no serious side effects reported. This suggests that psilocybin-assisted therapy combined with mindfulness training could be a promising treatment for depression and burnout among healthcare professionals.

Attitudes toward psychedelics and psychedelic-assisted therapy among potential mental health service users and the general population in Australia

mycolabadmin

This Australian study surveyed over 500 people about their views on psychedelics like psilocybin and MDMA for treating mental health conditions. Most people supported medical legalization of these substances, though many had safety concerns. Those with mental illness, those with prior psychedelic experience, and those with better knowledge of psychedelics were most supportive of their therapeutic use.

Treating job-related stress with psychedelic group therapy: a case series on group ketamine-assisted psychotherapy for healthcare workers and first responders

mycolabadmin

Researchers tested a new group therapy approach using ketamine to help firefighters, police officers, paramedics, and healthcare workers dealing with job stress and burnout. Over seven weeks, 32 participants received three ketamine sessions combined with group therapy. The results showed significant improvements in anxiety, depression, trauma symptoms, and burnout within the group. This low-cost group approach not only helped individual symptoms but also created a supportive community where workers felt understood by others in similar situations.

Epidemiology and outcomes of Candida-associated osteoarticular infections: A multicentre retrospective study from Turkey

mycolabadmin

This study examined 73 patients in Turkey who developed bone and joint infections caused by Candida fungi over ten years. The researchers found that diabetes was very common among patients and made recovery harder, while surgery to clean out infected tissue significantly improved outcomes. Importantly, they discovered resistance to common antifungal medications was higher in certain Candida species compared to others.

Evaluation of Clinical, Microbiological Profiles and Management Patterns with Outcomes of Patients with Fungal Isolates in An Intensive Care Unit of A Tertiary Care Center: A Prospective Observational Study

mycolabadmin

This study examined fungal infections in critically ill patients at a major hospital, tracking 120 patients and their fungal infections. Researchers found that diabetes was the most common risk factor, with most fungal infections occurring in urine samples and commonly caused by Candida tropicalis. The study revealed that many fungal strains were resistant to common antifungal drugs like fluconazole, suggesting that doctors need to carefully choose alternative treatments based on each patient’s specific infection type.

Breakthrough Invasive Mould Infections Under Posaconazole Prophylaxis in Patients With Haematologic Malignancies: A Case–Control Study

mycolabadmin

This study examined cases where patients receiving posaconazole to prevent fungal infections still developed serious mould infections despite the medication. Researchers compared 29 patients who developed these breakthrough infections with 46 control patients who did not. They found that over half of patients with breakthrough infections died, compared to only 20% of controls, and that surgical treatment significantly improved survival for certain types of fungal infections.

Research Keyword: clinical outcomes